Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

Summit Therapeutics' (SMMT) Phase 3 HARMONi trial results showed that ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) in EGFR-mutated non-small cell lung cancer patients, with a hazard ratio of 0.52 compared to chemotherapy alone; however, overall survival (OS) showed a positive trend but did not achieve statistical significance (HR=0.79, p=0.057), a key factor for FDA approval, leading the company to consider the timing of its Biologics License Application (BLA) filing, and the stock subsequently fell 12.3% in premarket trading.

Analysis

Summit Therapeutics (SMMT) reported mixed topline results from its Phase 3 HARMONi trial evaluating ivonescimab plus chemotherapy in EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) patients post-3rd generation EGFR TKI treatment. The trial successfully met one primary endpoint, demonstrating a statistically significant and clinically meaningful 48% reduction in disease progression risk (progression-free survival, PFS) with a hazard ratio (HR) of 0.52 compared to placebo plus chemotherapy. However, the other primary endpoint, overall survival (OS), showed a positive trend (HR=0.79) but did not achieve statistical significance (p=0.057) at the prespecified primary data analysis. This OS outcome is a critical hurdle, as the FDA has indicated that a statistically significant OS benefit is necessary for marketing authorization, influencing Summit's timing for a Biologics License Application (BLA) filing. The safety profile of ivonescimab plus chemotherapy was deemed acceptable and manageable; notably, fatal treatment-emergent adverse events (TEAEs), excluding disease progression, were lower in the ivonescimab arm (1.8%) versus the chemotherapy-alone arm (2.8%), although Grade 3 or higher TEAEs were more frequent (56.9% vs 50.0%). The market registered concern over the OS data and regulatory uncertainty, with SMMT stock declining 12.3% in premarket trading. Contextually, Summit's partner, Akeso, Inc., recently gained NMPA approval in China for ivonescimab for a second indication based on the HARMONi-2 trial, which showed an OS HR of 0.777, and also reported positive PFS data from the HARMONi-6 trial where ivonescimab plus chemotherapy outperformed BeiGene Ltd's Tevimbra plus chemotherapy.

Key Decisions for Investors

• Investors should carefully weigh the significant progression-free survival benefit of ivonescimab against the current lack of statistically significant overall survival, which presents a considerable regulatory risk for U.S. approval given FDA guidance.
• The pronounced negative premarket stock reaction highlights market apprehension regarding the OS data and subsequent approval pathway; thus, a cautious stance is warranted until greater clarity on the BLA submission strategy and potential for mature OS data to meet statistical significance is available.
• Monitor for updates on Summit's discussions with the FDA, the timing of the BLA filing, and any further OS data maturation from the HARMONi trial, while also considering the positive developments from partner Akeso in China and other ongoing trials as potential long-term differentiating factors that do not, however, mitigate the immediate U.S. regulatory uncertainty.